123 related articles for article (PubMed ID: 9202179)
1. Induction of embryonal carcinoma cell differentiation by deferoxamine, a potent therapeutic iron chelator.
Tanaka T; Muto N; Ido Y; Itoh N; Tanaka K
Biochim Biophys Acta; 1997 Jun; 1357(1):91-7. PubMed ID: 9202179
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis during iron chelator-induced differentiation in F9 embryonal carcinoma cells.
Tanaka T; Satoh T; Onozawa Y; Kohroki J; Itoh N; Ishidate M; Muto N; Tanaka K
Cell Biol Int; 1999; 23(8):541-50. PubMed ID: 10704238
[TBL] [Abstract][Full Text] [Related]
3. Induction of differentiation of embryonal carcinoma F9 cells by iron chelators.
Tanaka T; Muto N; Itoh N; Dota A; Nishina Y; Inada A; Tanaka K
Res Commun Mol Pathol Pharmacol; 1995 Nov; 90(2):211-20. PubMed ID: 8747790
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3.
Ido Y; Muto N; Inada A; Kohroki J; Mano M; Odani T; Itoh N; Yamamoto K; Tanaka K
Cell Prolif; 1999 Feb; 32(1):63-73. PubMed ID: 10371304
[TBL] [Abstract][Full Text] [Related]
5. p38 and ERK MAP kinase mediates iron chelator-induced apoptosis and -suppressed differentiation of immortalized and malignant human oral keratinocytes.
Lee SK; Jang HJ; Lee HJ; Lee J; Jeon BH; Jun CD; Lee SK; Kim EC
Life Sci; 2006 Sep; 79(15):1419-27. PubMed ID: 16697418
[TBL] [Abstract][Full Text] [Related]
6. The effect of iron overload and chelation on erythroid differentiation.
Taoka K; Kumano K; Nakamura F; Hosoi M; Goyama S; Imai Y; Hangaishi A; Kurokawa M
Int J Hematol; 2012 Feb; 95(2):149-59. PubMed ID: 22193844
[TBL] [Abstract][Full Text] [Related]
7. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
Brard L; Granai CO; Swamy N
Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
[TBL] [Abstract][Full Text] [Related]
8. Iron chelators induce apoptosis in proliferating cells.
Hileti D; Panayiotidis P; Hoffbrand AV
Br J Haematol; 1995 Jan; 89(1):181-7. PubMed ID: 7833261
[TBL] [Abstract][Full Text] [Related]
9. Iron chelator induces THP-1 cell differentiation potentially by modulating intracellular glutathione levels.
Seo GS; Lee SH; Choi SC; Choi EY; Oh HM; Choi EJ; Park DS; Kim SW; Kim TH; Nah YH; Kim S; Kim SH; You SH; Jun CD
Free Radic Biol Med; 2006 May; 40(9):1502-12. PubMed ID: 16632111
[TBL] [Abstract][Full Text] [Related]
10. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
Kim JL; Lee DH; Na YJ; Kim BR; Jeong YA; Lee SI; Kang S; Joung SY; Lee SY; Oh SC; Min BW
Tumour Biol; 2016 Jul; 37(7):9709-19. PubMed ID: 26803514
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo.
Jiang XP; Wang F; Yang DC; Elliott RL; Head JF
Anticancer Res; 2002; 22(5):2685-92. PubMed ID: 12529982
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines.
Bajbouj K; Shafarin J; Hamad M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818764470. PubMed ID: 29562821
[TBL] [Abstract][Full Text] [Related]
13. Effect of ferrous and ferric chelators on transferrin-iron-macrophage interactions.
Baynes RD; Friedman BM; Bukofzer GT; Bothwell TH; Macfarlane BJ; Lamparelli RD
Am J Hematol; 1988 Sep; 29(1):27-32. PubMed ID: 3177366
[TBL] [Abstract][Full Text] [Related]
14. Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors.
Baschant U; Rauner M; Balaian E; Weidner H; Roetto A; Platzbecker U; Hofbauer LC
Haematologica; 2016 Dec; 101(12):1499-1507. PubMed ID: 27540134
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells.
Simonart T; Boelaert JR; Mosselmans R; Andrei G; Noel JC; De Clercq E; Snoeck R
Gynecol Oncol; 2002 Apr; 85(1):95-102. PubMed ID: 11925126
[TBL] [Abstract][Full Text] [Related]
16. Effect of iron chelators on proliferation and iron uptake in hepatoma cells.
Kicic A; Chua AC; Baker E
Cancer; 2001 Dec; 92(12):3093-110. PubMed ID: 11753989
[TBL] [Abstract][Full Text] [Related]
17. Deferoxamine-conjugated AgInS
Phiwchai I; Thongtem T; Thongtem S; Pilapong C
Int J Pharm; 2017 May; 524(1-2):30-40. PubMed ID: 28359812
[TBL] [Abstract][Full Text] [Related]
18. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
20. Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron.
Haney SL; Varney ML; Safranek HR; Chhonker YS; G-Dayanandan N; Talmon G; Murry DJ; Wiemer AJ; Wright DL; Holstein SA
Leuk Res; 2019 Feb; 77():17-27. PubMed ID: 30612055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
